STAT6 plays a prominent role in adaptive immunity by transducing signals from extracellular cytokines. We now show that STAT6 is required for innate immune signaling in response to virus infection. Viruses or cytoplasmic nucleic acids trigger STING (also named MITA/ERIS) to recruit STAT6 to the endoplasmic reticulum, leading to STAT6 phosphorylation on Ser 407 by TBK1 and Tyr 641
INTRODUCTION
Innate immunity is the first line of defense against microbial infection. Recognition of pathogens is mainly mediated by pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), RIG-I-like receptors (RLRs) and NOD-like receptors (NLRs) (Takeuchi and Akira, 2010) , that trigger signal cascades to upregulate the expression of various cytokines. In the case of viral infection, endosomal TLRs and cytoplasmic RLRs detect viral DNAs or RNAs and induce the production of type I IFN, which are potent inhibitors of viral replication (Gitlin et al., 2006; Kato et al., 2005 Kato et al., , 2006 . RLRs, including RIG-I and Mda5, are sensors of viral RNAs in the cytoplasm; in response to viral infection, RLRs associate with the adaptor protein MAVS/Cardif/ IPS-1/VISA (Kawai et al., 2005; Meylan et al., 2005; Seth et al., 2005; Xu et al., 2005) , an integral membrane protein that functions on both mitochondria and peroxisomes through distinct mechanisms (Dixit et al., 2010) ; the RLR/MAVS complex facilitates TBK1/IKKε-mediated activation of IRF3/7 and NF-kB, which lead to the induction of type I IFNs. Besides viral RNA, cytoplasmic double-stranded DNA (dsDNA) also induces type I IFNs, but the exact identity of the receptor in this situation is currently not fully established Stetson and Medzhitov, 2006) . A recently identified adaptor protein, endoplasmic reticulum IFN stimulator (STING, also named MITA/ ERIS) (Ishikawa and Barber, 2008; Sun et al., 2009; Zhong et al., 2008 ) exhibits a vital role in dsDNA signaling (Ishikawa et al., 2009 ). The DNA sensors induce type I IFN production either through STING (IFI16 [Unterholzner et al., 2010] ) or via the RIG-I-MAVS axis (involving RNA polymerase III mediated transcription of cytoplasmic DNA [Ablasser et al., 2009; Chiu et al., 2009]) , and both pathways ultimately result in the recruitment and activation of TBK1, which in turn activates IRF3/7 and NF-kB.
Many cytokines, including type I IFNs, exert their effects through the canonical JAK (Janus kinase)-STAT (signal transducers and activators of transcription) pathway (Levy and Darnell, 2002) . Specifically, IL-4 and IL-13 activate STAT6 (Takeda et al., 1996) resulting in T helper cells 2 (T h 2) polarization (Akimoto et al., 1998; Hebenstreit et al., 2006; Shimoda et al., 1996) . IL-4 induces the phosphorylation of IL-4 receptor, which in turn recruits cytosolic STAT6 by its SH2 domain; the recruited STAT6 is phosphorylated on tyrosine 641 (Y 641 ) by JAK1, which results in the dimerization and nuclear translocation of STAT6 to activate target genes (Mikita et al., 1996 (Mikita et al., , 1998 . Several cytokines, including IL-3/15, IFN-a and platelet-derived growth factor (PDGF-BB), activate STAT6 in different cell types (Bulanova et al., 2003; Masuda et al., 2000; Quelle et al., 1995) , and induce over 150 diverse targets, many of which are involved in T h 2-associated processes (Elo et al., 2010; Wei et al., 2010) . A thorough understanding of biological consequences of STAT6 signaling awaits additional studies.
It is known that NF-kB, AP-1 and IRFs are responsible for the induction of many IFN-stimulated genes (ISGs), however, the role of STAT6 in anti-viral response is unclear. Here we report a STAT6-dependent antiviral innate immune signaling event that leads to the induction of chemokines, including CCL2, CCL20, and CCL26, and these chemokines recruit immune cells to combat viral infection. More importantly, virus induces STAT6 activation independently of JAK, but instead relies on STING and TBK1, as well as MAVS in the case of RNA virus. The physiological significance of the novel pathway is reflected by a higher susceptibility of Stat6 -/-mice to viral infections; moreover, unlike other cell type-specific STAT6 signaling pathways, virusinduced STAT6 activation is ubiquitously detected, implying a fundamental requirement of this mechanism in the defense against viral infections.
RESULTS

STAT6
Interacts with STING in Response to Virus Infection Using C-terminal STING (aa 178-379) as bait in the yeast 2-hybrid screen, we identified an STING-STAT6 interaction and confirmed it in 293 cells by coimmunoprecipitation (coIP) (Figure S1A available online) . Specifically, the DNA-binding domain (DBD) of STAT6 and STING C terminus (aa 317-379) were required for this interaction (Figures S1B-S1D). We next examined this interaction at endogenous protein levels. Analysis with confocal microscope showed a dispersed pattern of STAT6 in the cytosol of unstimulated HeLa cells; upon infection with Sendai virus (SeV, an RNA virus), STAT6 redistributes to the perinuclear regions, colocalizes with STING, and eventually translocates into the nucleus ( Figure 1A ). CoIP analyses also revealed an inducible interaction of endogenous STAT6 with STING, as well as MAVS and TBK1, in SeV-infected primary MEFs, 2fTGH and THP-1 cells ( Figure 1B ). Consistent with these observations, endogenous STAT6 co-fractionate with STING in HeLa cell lysates after Herpes simplex virus 1 (HSV-1, a DNA virus) infection ( Figure 1C ). Similar results were obtained from SeV-infected HeLa cells, with an additional location to a mixed fraction containing MAVS-resident mitochondria-associated ER membrane (MAM) and also MAVS-resident peroxisomal membrane (Dixit et al., 2010; Ishikawa et al., 2009; Zhong et al., 2008) (Figure 1D ). These data demonstrate that STAT6 interacts with STING during virus infection.
STAT6 Is Activated upon Virus
Infection 293 cells lack a functional endogenous STAT6 but express the other components of the IL-4 signaling pathway (Mikita et al., 1996 (Mikita et al., , 1998 . Taking advantage of this property, we first established a 293 cell-line stably expressing Flag-STAT6 (293-STAT6) and confirmed its normal responsiveness to IL-4/13 with intact Y 641 phosphorylation (data not shown). Virus infection resulted in the nuclear translocation of STAT6, suggesting that STAT6 may serve as a transcriptional activator under this situation. To confirm this hypothesis, we assessed Y 641 phosphorylation of STAT6, since it is required for STAT6 activation in response to cytokines. We found that STAT6 was indeed phosphorylated on Y 641 in SeV-infected and poly (I:C)/poly dAdT-transfected cells, and this STAT6 phosphorylation takes place prior to the phosphorylation of IRF3 and other STATs (Figures 2A, 2D, and 2H, and Figures S2B and S2H) . A STAT6-responsive luciferase reporter (E3-Luc) (Yuan et al., 2006) was activated in 293-STAT6 cells upon virus infection and poly (I:C)/poly dAdT transfection, whereas a nonresponsive control reporter (mutated at the STAT6-binding site, E3-Luc-M) was not affected ( Figure 2C and Figure S2A ). By contrast, neither reporter was activated in 293 cells, indicating a transactivation function of STAT6 in response to virus. These findings imply a previously unknown pathway of STAT6 activation in response to viral infection and cytoplasmic dsRNA/DNA. STAT6 can be activated by several cytokines. To clarify a potential role of cytokines in STAT6 activation during viral challenges, we first monitored cytokine production in virus-infected cells. Neither IL-4 nor IL-13 was induced by virus ( Figure 2B Figure S1 .
and Figure S2C ), thus excluding their involvement in STAT6 activation after virus infection. Strikingly, other cytokines including type I IFNs, IL-8 and STAT6-induced genes (CCL2 and CCL20, see below), displayed similar kinetics post infection. Therefore, CCL2/20 is unlikely regulated by cytokines like type I IFNs or IL-8. In fact, when media of SeV-infected 293-STAT6 cells were used to treat naive 293-STAT6 cells, STAT6 phosphorylation was only detected in virus-infected but not media-treated cells, whereas phosphorylation of STAT1/2/3/5 was detected in media-treated cells ( Figure 2D and data not shown), excluding any STAT6-activating cytokines in the media within these time points. Furthermore, STAT6 phosphorylation was intact upon SeV and poly (I:C) stimulation when production of cytokines including IL-8 and type I IFNs was inhibited by cycloheximide (CHX) pretreatment (Figures 2E and 2F) . These data collectively indicate a cytokine -independent pathway of STAT6 activation upon virus infection. Next we used 2fTGH and its derivative cell lines (Kumar et al., 1997) (each deficiency in a single key component of the JAK-STAT pathway, Figure S2D ) to test if any of these known proteins in JAK-STAT pathway would be required for virus-induced STAT6 activation. Notably, U4A cells with JAK1 deficiency did Figure S2G ), indicating that none of these components alone is indispensable. Besides, cytokine effects were re-examined using these cells. Treatment with a high concentration of IFNs and other STAT6-responding cytokines including IL-3/15 and PDGF-BB did not result in STAT6 phosphorylation in 2fTGH or U5A cells ( Figure 2H , Figure S2F , and data not shown), supporting our previous conclusion that virus-induced STAT6 activation is cytokine-independent. Although virus-induced STAT6 activation appears to be quite different from that induced by IL-4/13, Y 641 phosphorylation is essential for both activation pathways since mutation of this residue totally abolished its response to virus or IL-4/13 (Figure 2I) . The SH2 domain of STATs is essential not only for both receptor-binding and dimerization, but is also required for DNA binding by this family of proteins. To investigate the role of SH2 domain in virus-induced STAT6 activation, we searched for potential residue(s) in this domain that might be important. We found that L 551 A mutant lost the ability to respond to virus, albeit with normal response to IL-4/13, and the defect was fully rescued by the reversion mutation ( Figures S2I-S2L ). Further experiments showed that the L 551 A mutation abrogated Y 641 phosphorylation and STAT6 homo-dimerization in response to virus; by contrast, the mutation has no effect on STAT6 activation by IL-4 ( Figures S2M-S2O ). Collectively these data suggest that STAT6 is differentially activated by virus and IL-4/13. 
Virus-Activated STAT6 Regulates a Specific Set of Target Genes
Using DNA microarrays, we compared mRNAs that are significantly induced in mock or poly (I:C) transfected 293 and 293-STAT6 cells. Among 30, 968 genes examined, poly (I:C) transfection induced the expression of numerous ISGs in both cells, including OAS1, CCL5 and IFIT1/3, and a set of genes only in 293-STAT6 cells ( Figure 3A) , suggesting that these genes are specifically regulated by STAT6; notably among the STAT6-regulated genes are the chemokines CCL2, CCL20, and CCL26, which are responsible for the recruitment of immune cells to sites of infection. The microarray data were validated by either quantitative-PCR or ELISA ( Figures 3B and 3C and Figure S3 ), respectively.
The transcriptome of poly (I:C) stimulated 293-STAT6 cells displayed substantial difference from that of IL-4/13 activated cells. In fact, while CCL11 was only upregulated by IL-4 treatment, CCL26 could be induced by both IL-4 and virus. Consistently, both SeV and poly (I:C) were able to induce CCL2 and CCL20 in U4A and U5A cells ( Figures 3B and 3C) . Furthermore, inspection of CCL2 promoter sequence revealed one typical and two putative STAT6 binding sites (-1129 to -1120, -585 to -576, and -293 to -285 relative to the transcriptional start site, respectively). SeV and HSV-1 infection indeed activated a luciferase reporter driven by DNA segment containing these sites, but not the one with mutation in the first STAT6 binding site ( Figure 3D ), suggesting that CCL2 promoter harbors a functional STAT6 binding site that is responsive to virus infection.
STING Mediates STAT6 Activation by Virus
Next, we sought to investigate the molecular mechanism of STAT6 signaling in response to virus. The translocation and interaction of STAT6 with STING after virus infection (Figure 1 ) raised the possibility that STING is involved in STAT6 activation.
To address this possibility, we first assessed the effect of RNAi knockdown of STING. Suppression of STING expression almost completely abolished STAT6 activation in response to SeV infection, but had little effects on IL-4 treatment ( Figures S4A-S4C) . Meanwhile, the induced interaction between MAVS and STAT6 ( Figure S4D ) and translocation of STAT6 from cytosol to ER fraction and later to nucleus was barely detectable (Figure S4E) . Further evidence for a critical role of STING in virusderived STAT6 activation showed that Sting -/-MEFs lost CCL2/20 induction in response to virus and transfected genomic DNA, although comparable amounts of IL-6 and type I IFNs were detected in response to SeV, VSV, and poly (I:C) ( Figure 4A ). This result also demonstrated that STING is dispensable for RLR-mediated type I IFN production. As a control, WT and STING-reconstituted Sting À/À MEFs showed normal response, highlighting the vital role of STING in virus-induced STAT6 activation. STAT6 from Sting À/À MEFs retained in the cytosol after virus infection ( Figure 4B ). Exogenous human STAT6 (hSTAT6) was not phosphorylated on Y 641 ( Figure 4C ), nor did it dimerize ( Figure 4D ) in Sting À/À MEFs after virus infection.
These data as a whole indicated that STING is required for virus-induced STAT6 activation.
MAVS Is Required for STAT6 Activation by RNA Virus
Since STAT6 was also localized to MAVS-resident MAM and peroxisomes ( Figure 1D ), we speculated that MAVS might take a part in STAT6 signaling after virus infection. Indeed, MAVS, RIG-I-N, and Mda5-N (where N denotes N-terminal CARD module) strongly activated STAT6 ( Figure S5A ), consistent with a role for STAT6 in RNA virus infection. Yeast 2-hybrid assays showed that STAT6 interacted only with STING but not with MAVS or TBK1, each of which could bind STING ( Figure S5B ). This result suggested that STING may act as a platform that assembles the STAT6 signal complex which includes MAVS in the case of RNA virus stimulation. Figure 5C ). In addition, SeV-induced STAT6 nucleus translocation was completely abolished in Mavs À/À cells (data not shown). The requirement for MAVS in STAT6 signaling was confirmed by that virus-induced CCL2/20 production was fully restored in human MAVS-reconstituted Mavs À/À MEFs (Figure 5D ). These data demonstrate that MAVS is required for RNA virus-induced STAT6 activation. We also investigated the role of STING and MAVS in the canonical STAT6 pathway, and we observed normal CCL11 induction in relevant knockout MEFs in response to IL-4 except Stat6 À/À MEFs ( Figure 5E ), suggesting that the canonical STAT6 signaling pathway is intact and is independent of STING or MAVS.
TBK1 Is Required for STAT6 Phosphorylation
Our previous results suggest that individual JAK deficiency has little effect on virus-triggered STAT6 phosphorylation, but it remains to be tested whether simultaneous lack of two or more JAKs would inhibit the process. Using Jak inhibitor Ruxolitinib (INCB 018424) and CP690550, which show specific inhibition of JAK1/2 and JAK3/JAK2, respectively, we found that the inhibitors had little impact on virus-induced STAT6 phosphorylation in U1A cells that is deficient of Tyk2 protein ( Figure 6A ). Consistently, none of the JAKs was phosphorylated in virus-infected U5A cells while STAT6 phosphorylation persisted ( Figure 6B ), implying a JAK-independent phosphorylation of STAT6. Interestingly, TBK1, IKKε, and IKKb overexpression led to obvious shift in the mobility of STAT6 on SDS-PAGE ( Figure 6C ), whereas no other STATs were affected ( Figure S6A ), suggesting that STAT6 can be phosphorylated and activated by these kinases, as supported by the observation that TBK1/IKKε promoted STAT6 activation in reporter assays ( Figure S6B ).
To systematically search for STAT6 phosphorylation site, we individually mutated most of the conserved serines, threonines and tyrosines on STAT6, and found that S 407 A and T 572 A showed no response to virus but responded to IL-4/13 perfectly (Figure S6C ), indicating that S 407 or T 572 might be critical sites in virus-induced but not IL-4/13-induced STAT6 activation. Importantly, S 407 lies within a consensus motif for TBK1 phosphorylation (Soulat et al., 2008) , which was confirmed by in vitro kinase assay ( Figure 6E ). TBK1 IP-ed from 293 cells infected with SeV was found to phosphorylate STAT6 but not STAT2 or STAT3. Furthermore, phosphorylation of peptide 358-427 was greatly impaired when S 407 was mutated. Besides, no TBK1 phosphorylation site was indicated in regions 1-358 or 427-610, thus T 572 is unlikely the target site of TBK1. We also found evidence for the existence of other TBK1 phosphorylation site(s) on the C terminus of STAT6. These data suggest that TBK1 phosphorylates STAT6 in response to virus infection.
Consistently, TBK1 deficiency wiped out STAT6 phosphorylation by poly (I:C) transfection ( Figure 6F ) and abolished upregulation of STAT6-dependent genes both at the mRNA level (Figure S6D ) and the protein level ( Figure 6G ). Reconstitution of Tbk1 À/À MEFs with WT, but not kinase-dead TBK1 (KD-TBK1) restored STAT6 activation, emphasizing the importance of TBK1 kinase activity. These data collectively indicate that TBK1 plays an essential role in STAT6 phosphorylation and activation during virus infection.
STAT6 Is Required for Antiviral Immunity In Vivo
Finally we assessed the physiological function of STAT6 using Stat6 À/À mice and cells. STAT6 was required for virus-, but not TLR-induced CCL2/20 production in peritoneal macrophages ( Figure 7A ), suggesting that the new activation circuit is restricted to intracellular nucleic acids. Notably, CCL2 production was completely lost in sera and in organs from Stat6 À/À mice intravenously infected with virus while CCL20 induction was only partially impaired ( Figures 7C and 7D) , suggesting an absolute STAT6-dependence for CCL2 induction and a partial STAT6-reliance for CCL20 expression. The same was true for macrophages, BMDMs and MEFs ( Figures 7A and 7B and Figure S7B ). We also investigated whether virus-induced STAT6 signaling involves other virus-activated transcription factors or components including NF-kB and IRF3. Inhibition of NF-kB by IkB-SR (Brockman et al., 1995) overexpression did not affect virusinduced CCL20 production while slightly reduced CCL2 production ( Figure S7A) ; in parallel experiments, IRF3 deficiency showed no effects at all ( Figure 7B ). This result indicates that neither NF-kB nor IRF3 is critical for virus-induced STAT6 signaling, suggesting that the bifurcating of STAT6-medieated signaling occurs at an early stage. Data in MEFs and BMDMs from WT, Il-4r -/-and Stat6 À/À mice supported a requirement for STAT6 but not IL-4/IL-4R in virus-induced cytokine production ( Figures 7B and 7I and Figure S7B ). Severe infiltration of monocytes was observed in the lungs of WT and Il-4r -/-mice, compared to no infiltration in those of Stat6 À/À mice after virus infection ( Figure 7E and Figure S7C ). In accordance with the above results, virus titer in the lungs and livers of Stat6 demonstrating that distinct mechanisms are employed by cells to activate STAT6 in response to diverse challenges.
DISCUSSION
The present study shows that STAT6 is activated by intracellular non-self nucleic acids which lead to innate immune activation. STAT6 activated in this manner regulates a specific set of genes that are required for the recruitment of various immune cells to the site of infection. The mechanism employed for STAT6 activation by virus is distinct from that by cytokines like IL-4/13 in the canonical pathway ( Figure S7F ). Thus, our study identifies a previously unknown STAT6 activating cascade which plays a critical role in innate immunity against microbial infection.
Virus Infection Triggers a Cell Intrinsic Pathway of STAT6 Activation
We have presented several lines of evidence indicating that virus infection triggers a cell intrinsic pathway leading to STAT6 activation. First, STAT6 phosphorylation occurred prior to (or no later than) the phosphorylation of IRF3 and other STATs, supporting a primary response of STAT6 to virus infection. Second, upon virus infection, STAT6-regulated chemokines were upregulated simultaneously with type I IFNs and IL-8. Third, virus-induced STAT6 phosphorylation persisted in cycloheximide-pretreated cells that are unable to carry out protein synthesis. Fourth, condition medium-treated cells showed STAT1/3/5 phosphorylation, but not STAT6 phosphorylation. Fifth, virus-activated STAT6 regulates a specific set of genes involved in immune cell homing; these target genes are different from most of known STAT6-regulated genes. Finally, STAT6 point mutation revealed a distinct activating mechanism employed by cells in response to virus. Based on the data presented, we proposed a working model for STAT6 activation in response to intracellular nucleic acids ( Figure S7F ), in which STING plays a central role to integrate signals coming from both RNA and DNA virus infection. Upon DNA virus infection, STING is first activated and then recruits STAT6. TBK1 is also recruited by STING to phosphorylate STAT6 on S 407 , which in turn activates another unidentified tyrosine kinase to phosphorylate STAT6 on Y 641 , leading to the homodimerization and nucleus translocation of STAT6. STAT6 interacted with TBK1 constitutively, in a way that probably affected TBK1 phosphorylation of STAT6 (data not shown). Moreover, our studies in STAT2-deficient cells exclude the formation of STAT2/STAT6 heterodimers reported before (Gupta et al., 1999 relevance of S 407 phosphorylation will be further tested if a STAT6 antibody recognizing this phosphorylated site is available.
Virus induces different STAT6 target genes compared to IL-4/ 13. We interpret the specificity as a possible result of conformation change in STAT6 dimers that favor distinct target sequences, since S 407 phosphorylation is unique to virus infection. Also, cofactor(s) may be required that differentially respond to virus and IL-4/13.
Virus-Activated STAT6 Induces Specific Chemokines
Virus triggers STAT6 to induce a set of chemokines capable of attracting various immune cells: CCL2 for monocytes, macrophages and T cells, etc. (Yadav et al., 2010) ; CCL20 for CCR6-expressing B cells, T cells and dendritic cells; CCL26 for eosinophils, basophils and subsets of NK cells, etc. (Nakayama et al., 2010) . Deregulation of these chemokines are involved in diseases associated with the infiltration of immune cells (Boring et al., 1998; Gosling et al., 1999; Harper et al., 2009; Hedrick et al., 2009; Weckmann et al., 2007) . Interestingly, CCL2 and CCL20 can be induced by various stimuli including mammalian and bacterial DNA in a TBK1/IKKε-dependent manner , but the role of STAT6 in these situations has not been reported. CCL26 is found only in human and is differently regulated by STAT6 in response to IL-4/13 and virus. We observed much less infiltration of immune cells and higher viral loads in organs of virus-infected Stat6 -/-mice. Consistently,
Stat6
-/-mice are more susceptible to virus than their WT and Il-4r -/-counterparts. The findings explain the hypersensitivity of knockout mice to virus as an outcome of delayed or inadequate immune cell recruitment due to impaired chemokine production ( Figures 7E and S7C ), supported by abundant cases (Hokeness et al., 2005; Jia et al., 2008) . Recently Toxoplasma gondii infection was shown to induce STAT6 P-Y 641 and activation in HeLa cells independent of IL-4, but the mechanism was unclear (Ahn et al., 2009 -/-mice on a BALB/c background were obtained from Max Delbruck Center for Molecular Medicine as described previously , Mavs +/-mice on a 129/Sv/C57BL/6 background were a kind gift from Dr. Zhijian J. Chen. BALB/c mice were purchased from Laboratory Animal Center. Mice were kept and bred in pathogen-free conditions. All animal studies were conducted at the AAALACapproved Animal Facility in the Laboratory Animal Center of Peking University. Experiments were undertaken in accordance with the National Institute of Health Guide for Care and Use of Laboratory Animals, with the approval of Peking University Laboratory Animal Center, Beijing.
Coimmunoprecipitation, Immunoblot Analysis, Native PAGE, RT-PCR, RNAi, Type I IFN Bioassay, Luciferase Reporter Assay, VSV Plaque Assays, and Subcellular Fractionation These experiments were performed as previously described You et al., 2009 ).
Yeast Two-Hybrid Screening
The experiment was performed as previously described ). C-terminal human STING (aa 178-379) was used as bait to screen a human leukocyte cDNA library (Clontech, Palo Alto, CA).
Immunofluorescent Confocal Microscopy
The experiments were performed as described ). Imaging of the cells was carried out using Leica TCS SP2 confocal system under a 3 100 oil objective.
In Vitro Kinase Assay
The experiment was performed as previously described (Jiang et al., 2002) with minor modification. Human STATs WT or truncation coding sequences were cloned into pGEX-KG. GST protein was purified with glutathione-agarose beads and eluted by glutathione. Purified proteins were examined by SDS-PAGE and Coomassie blue staining. TBK1 immunoprecipitants were incubated with 1 mg purified GST protein in 20 ml kinase buffer containing 10 mM HEPES (pH 7.4), 1 mM dithiothreitol, 5 mM MgCl 2 and 5 mCi of g 32 P-ATP (3000 Ci/mM) at 25 C for 15 min. Samples were resolved by SDS-PAGE, dried and visualized by autoradiography.
Microarray Analysis RNA was extracted with Trizol (Invitrogen) and verified with RNA integrity number (RIN). The aminoallyl-RNA (aRNA) probes labeled with NHS-Cy5 (Amersham) were hybridized at 50 C for 16 hr to the Human Whole Genome
OneArray TM Version 4.3 (PhalanxBiotech Group, Taiwan), scanned with Axon 4000B Scanner (Molecular Devices, USA) and analyzed with Genepix software (Molecular Devices USA). Array data are available at Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under the accession number GSE26435. Detailed procedures are described in the Extended Experimental Procedures.
Lung Histology
Lungs from control or virus-infected mice were dissected, fixed in 10% phosphate-buffered formalin, embedded into paraffin, sectioned, stained with hematoxylin-eosin solution and examined by light microscopy for histologic changes.
Isolation of MEFs, BMDMs, and Macrophages
Embryonic fibroblasts (MEFs) from WT and mutant mice were prepared from day 15 embryos and cultured in DMEM supplemented with 10% FBS. Bone marrow derived macrophages (BMDMs) were isolated from tibia and femur. Cells were cultured in 10 cm Petri-dish at 37 C for 5 days. At day 3, 5 ml medium (DMEM with 20% FBS, glutamine and 30% L929 supernatant) was added. Peritoneal macrophages were harvested from mice 4 days after thioglycollate (BD, Sparks, MD) injection, and cultured in DMEM supplemented with 5% FBS. Cells were plated into 24-well plates and cultured in the absence or presence of LPS (100 ng/ml), MALP-2 (100 ng/ml) and CpG (100 nM) for 6 hr, or infected with the indicated virus for 24 hr. Cytokine production was analyzed by ELISA or bioassay.
Virus Infection
Cells were infected with SeV (0.1 multiplicity of infection (M.O.I.)), HSV-1(5 M.O.I.) or VSV (1 M.O.I) for 1 h; cells were washed with PBS and cultured in fresh media. Cytokine production was analyzed 24 hr later. For in vivo cytokine production studies, age-and sex-matched groups of mice were intravenously infected with HSV-1 (1.4 3 10 7 pfu per mouse), VSV (5 3 10 7 pfu per mouse) or SeV (1 000 TCID 50/ml, 200 ml per mouse). 
Statistical Analysis
